Related references
Note: Only part of the references are listed.Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2014)
Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes
Christopher A. Barker et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
Ronald Levy et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer
Michael A. Morse et al.
ANNALS OF SURGERY (2013)
Delayed urticarial reactions in the phase II trial of HER2/neu peptide vaccines plus GM-CSF vs. GM-CSF alone in high risk breast cancer patients
Alfred F. Trappey et al.
CANCER RESEARCH (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Therapeutic live vaccines as a potential anticancer strategy
Azam Bolhassani et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CD8(+) lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Use of Booster Inoculations to Sustain the Clinical Effect of an Adjuvant Breast Cancer Vaccine From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2011)
The Present and Future of Peptide Vaccines for Cancer Single or Multiple, Long or Short, Alone or in Combination?
Craig L. Slingluff
CANCER JOURNAL (2011)
Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
Stephen J. Schuster et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A clinically relevant gene signature in triple negative and basal-like breast cancer
Achim Rody et al.
BREAST CANCER RESEARCH (2011)
Results of the First Phase 1 Clinical Trial of the HER-2/neu Peptide (GP2) Vaccine in Disease-Free Breast Cancer Patients
Mark G. Carmichael et al.
CANCER (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
Jeremy D. Gates et al.
VACCINE (2010)
Bacteria in cancer therapy: a novel experimental strategy
S. Patyar et al.
JOURNAL OF BIOMEDICAL SCIENCE (2010)
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
Arnold Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Longterm Followup Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients
Jeremy D. Gates et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence - From US Military Cancer Institute clinical trials group study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2008)
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine:: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Asna Amin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Promises and challenges for the development of Listeria monocytogenes-based immunotherapies
Dirk G. Brockstedt et al.
EXPERT REVIEW OF VACCINES (2008)
Monitoring circulating tumor cells in cancer vaccine trials
J. D. Gates et al.
HUMAN VACCINES (2008)
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
Ilaria Marigo et al.
IMMUNOLOGICAL REVIEWS (2008)
Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine
Jarrod P. Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
Ping-Ying Pan et al.
BLOOD (2008)
Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain
Ioannis F. Voutsas et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
Nectaria N. Sotiriadou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
Elizabeth A. Mittendorf et al.
CANCER (2006)
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
GE Peoples et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients
MT Hueman et al.
CLINICAL CANCER RESEARCH (2005)
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
JL Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours
PA Sotiropoulou et al.
BRITISH JOURNAL OF CANCER (2003)
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity
C Melani et al.
BLOOD (2003)
Pilot study of an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant
DG McNeel et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2003)
Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide
RE Humphreys et al.
VACCINE (2000)
Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
CL Hsieh et al.
HUMAN GENE THERAPY (2000)
Share Paper
